Search hospitals > Quebec > SHERBROOKE
CIUSSS de l'Estrie - CHUS
Claim this profileSHERBROOKE, Quebec J1H 5N4
Conducts research for Crohn's Disease
Conducts research for Squamous Cell Carcinoma
Conducts research for Lymphoma
Conducts research for Arthritis
Conducts research for Cancer
45 reported clinical trials
3 medical researchers
Summary
CIUSSS de l'Estrie - CHUS is a medical facility located in SHERBROOKE, Quebec. This center is recognized for care of Crohn's Disease, Squamous Cell Carcinoma, Lymphoma, Arthritis, Cancer and other specialties. CIUSSS de l'Estrie - CHUS is involved with conducting 45 clinical trials across 80 conditions. There are 3 research doctors associated with this hospital, such as Paul Bessette, MD, Éric Turcotte, MD, and Martin Lepage, PhD.Area of expertise
1Crohn's Disease
2Squamous Cell Carcinoma
p16 positive
Stage III
Stage IV
Top PIs
Paul Bessette, MDCHUS - Hôpital Fleurimont4 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
8 reported clinical trials
12 drugs studied
Éric Turcotte, MDCentre de recherche du CHUS1 year of reported clinical research
Studies Contagious Diseases
Studies Infectious Diseases
6 reported clinical trials
9 drugs studied
Martin Lepage, PhDDouglas Mental Health University Institute6 years of reported clinical research
Studies Schizophrenia
Studies Psychosis
6 reported clinical trials
10 drugs studied
Clinical Trials running at CIUSSS de l'Estrie - CHUS
Follicular Lymphoma
Lymphoma
Marginal Zone Lymphoma
Hodgkin's Lymphoma
Endometrial Cancer
Colorectal Cancer
Lymphoid Leukemia
Chronic B-Cell Leukemia
Chronic Lymphocytic Leukemia
Leukemia
Odronextamab vs Chemotherapy
for Follicular Lymphoma
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be made up of two parts: Part 1 (non-randomized) and Part 2 (randomized - controlled). The aim of Part 1 of the study is to see how safe and tolerable the study drug is when given alone. The aim of Part 2 of the study is to see how the study drug works compared to rituximab (called the "comparator drug") and chemotherapy (the current standard of care for NHL). Standard of care means the usual medication expected and used when receiving treatment for a condition. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) * How the study drug affects quality of life and ability to complete routine daily activities.
Recruiting2 awards Phase 35 criteria
Zanubrutinib + Anti-CD20
for Lymphoma
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R\^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.
Recruiting2 awards Phase 35 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at CIUSSS de l'Estrie - CHUS?
CIUSSS de l'Estrie - CHUS is a medical facility located in SHERBROOKE, Quebec. This center is recognized for care of Crohn's Disease, Squamous Cell Carcinoma, Lymphoma, Arthritis, Cancer and other specialties. CIUSSS de l'Estrie - CHUS is involved with conducting 45 clinical trials across 80 conditions. There are 3 research doctors associated with this hospital, such as Paul Bessette, MD, Éric Turcotte, MD, and Martin Lepage, PhD.